354
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

ORCID Icon, &
Pages 481-484 | Received 19 Mar 2023, Accepted 21 Jul 2023, Published online: 13 May 2024

Figures & data

Figure 1. Clinical drivers for the choice of best medical therapy for patients with squamous cell carcinoma of the head and neck made by a multidisciplinary group.

Figure 1. Clinical drivers for the choice of best medical therapy for patients with squamous cell carcinoma of the head and neck made by a multidisciplinary group.

Table 1. Therapeutic algorithm for the treatment of SCCHN (squamous cell carcinoma of the head and neck) according to CPS score.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.